Table 1.
Summary of patients
| Case | Age/sex | Number | Distribution | Size (cm) | Dose Gy (RBE)/fr | Precedent therapy | Concurrent therapy | Adjuvant therapy | Survival period (years) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 69/F | S | Uni | 2 | 72.6/22 | C | N | N | 11.0 |
| 2 | 76/F | S | Uni | 4 | 72.6/22 | C | C | N | 8.4 |
| 3 | 61/M | M | Uni | 6 | 70/35 | C | N | N | 6.4 |
| 66/10 | |||||||||
| 4 | 77/M | S | Uni | 2 | 66/10 | N | C | C | 5.5 |
| 5 | 77/M | S | Uni | 4 | 72.6/22 | C | N | C | 4.5 |
| 6 | 71/M | M | Bi | 5 | 72.6/22 | C | N | N | 3.8 |
| 72.6/22 | |||||||||
| 7 | 78/M | s | Uni | 2 | 64/32 | C | N | C | 3.0 |
| 8 | 56/M | S | Uni | 3 | 72.6/22 | C | N | N | 2.3 |
| 9 | 59/M | M | Bi | 2 | 77/35 | C | C | C | 1.2 |
| 66/10 |
S = solitary, M = multiple, Uni = unilateral lobe, Bi = bilateral lobes, C = chemotherapy, N = none. Underlining indicates the cases who are still alive at the final follow-up (April–June 2016).